Drug intelligence / Profile preview

PGX + alginate

Development stage: Preclinical
Lead developer: Ceapro
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

PGX-alginate is a drug delivery technology platform developed by Ceapro Inc. that utilizes Pressurized Gas eXpanded (PGX) liquid technology to process sodium alginate into high-surface-area, highly porous scaffolds. These scaffolds, which can reach surface areas of approximately 200 m²/g, are designed to be loaded with active pharmaceutical ingredients—including hydrophobic drugs like ibuprofen—and can be crosslinked with calcium to form hydrogels. The technology is primarily being investigated for applications in burn wound healing, where the porous matrix supports tissue regeneration and provides controlled local delivery of therapeutic agents.

Other names: PGX-processed sodium alginatePGX-alginate scaffolds

Beyond the preview

Go deeper on PGX + alginate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGX + alginate.

Explore the full profile